文献速递创伤与烧伤复苏、休克与脓毒症

无静脉通路亦可行:猪出血模型中氨甲环酸骨内给药与静脉给药等效

No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论猪失血性休克模型显示,骨内注射氨甲环酸逆转纤溶亢进与静脉给药等效,静脉通路无法建立时可考虑骨内给药。

该研究采用猪失血性休克及缺血再灌注模型,18头猪在失血性休克后输注组织型纤溶酶原激活剂诱导纤溶亢进,随后随机接受静脉或胫骨骨内氨甲环酸输注10分钟。结果显示骨内给药在30分钟时即纠正EX-TEM和IN-TEM的溶解指数,与静脉给药类似;静脉与骨内给药峰浓度分别为160.9 μg/mL和132.57 μg/mL(p=0.053),峰浓度出现在输注结束时,监测4小时后两组血浆浓度相当。作者结论为骨内给予氨甲环酸逆转纤溶亢进与静脉等效,当静脉通路无法建立时可考虑骨内给药。

要点

  • 猪失血性休克模型中,骨内给予氨甲环酸在30分钟时纠正EX-TEM和IN-TEM溶解指数,效果与静脉给药类似。
  • 静脉与骨内氨甲环酸峰浓度分别为160.9 μg/mL和132.57 μg/mL(p=0.053),峰浓度均出现在10分钟输注结束时。
  • 监测4小时结束时,骨内与静脉给药的血浆氨甲环酸浓度相当。
  • 作者认为,在失血性休克且静脉通路无法建立时,可考虑骨内给予氨甲环酸。

适用人群与场景

  • 猪失血性休克及缺血再灌注模型,共18头猪,经组织型纤溶酶原激活剂输注诱导纤溶亢进。

处置流程与药物剂量

  • 动物在接受静脉或胫骨骨内氨甲环酸输注时,于10分钟内完成给药。

研究设计与关键结果

  • 研究类型为猪失血性休克及缺血再灌注模型,样本量18头猪,比较静脉与胫骨骨内给予氨甲环酸。
  • 出血及缺血再灌注后,两组平均动脉压(48 vs. 49.5)、乳酸(11.1 vs. 10.8)和pH(7.20 vs. 7.22)无显著差异。
  • 骨内给予氨甲环酸在30分钟时纠正EX-TEM和IN-TEM的溶解指数,与静脉输注类似。
  • 静脉与骨内给药峰浓度分别为160.9 μg/mL和132.57 μg/mL(p=0.053),峰浓度出现在输注结束时。
  • 监测4小时结束时,两组血浆氨甲环酸浓度相当,骨内给药与静脉给药具有相似的峰浓度、药代动力学和清除。

证据类型、等级与局限

  • 证据类型为动物实验(猪出血模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在失血性休克且静脉通路无法建立时,可考虑骨内给予氨甲环酸。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The acute coagulopathy of trauma is often accompanied by hyperfibrinolysis. Tranexamic acid (TXA) can reverse this phenomenon, and, when given early, decreases mortality from bleeding. Establishing intravenous (IV) access can be difficult in trauma and intraosseous (IO) access is often preferred for drug administration. Currently, there are no data on the efficacy of IO administered TXA. Our objectives were to compare serum concentrations of TXA when given IV and IO and to compare the efficacy of IO administered TXA to IV at reversing hyperfibrinolysis.

METHODS: Using a porcine hemorrhage and ischemia-reperfusion model, 18 swine underwent hemorrhagic shock followed by a tissue plasminogen activator infusion to induce hyperfibrinolysis. Animals then received an IV or tibial IO infusion of TXA over 10 minutes. Blood was then analyzed using rotational thromboelastometry to monitor reversal of hyperfibrinolysis. Serum was analyzed for drug concentrations.

RESULTS: After hemorrhage and ischemia-reperfusion, there were no significant differences in mean arterial pressure (48 vs. 49.5), lactate (11.1 vs. 10.8), and pH (7.20 vs. 7.22) between groups. Intraosseous TXA corrected the lysis index at 30 minutes in EX-TEM and IN-TEM, like IV infusion. Peak serum levels of TXA after IV and IO administration show concentrations of 160.9 μg/mL and 132.57 μg/mL respectively (p = 0.053). Peak levels occurred at the completion of infusion. Drug levels were tracked for four hours. At the end of monitoring, plasma concentrations of TXA were equivalent.

CONCLUSION: Intraosseous administration of TXA is as effective as IV in reversing hyperfibrinolysis in a porcine model of hemorrhagic shock. Intraosseous administration was associated with a similar peak levels, pharmacokinetics, and clearance. Intraosseous administration of TXA can be considered in hemorrhagic shock when IV access cannot be established.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Lallemand MS, Moe DM, McClellan JM, et al. No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model. J Trauma Acute Care Surg. 2018. PMID: 29194320. doi:10.1097/TA.0000000000001741

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。